openPR Logo
Press release

Pancreatic Cancer Pipeline Drugs Review H1 2017

07-06-2017 02:24 PM CET | Health & Medicine

Press release from: ReportsandReports

Pancreatic Cancer Pipeline Review H1 2017 provides an overview of the Pancreatic Cancer (Oncology) therapeutics pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

For More on Pancreatic Cancer Pipeline Review H1 2017 report inquire @ https://tinyurl.com/Pancreatic-Cancer-Pipeline .

Report Description:

Pharmaceutical guide Pancreatic Cancer - Pipeline Review H1 2017 guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type and reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 16, 120, 121, 2, 8, 273, 36 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 20, 9, 52 and 6 molecules, respectively.

The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Get Discount on Report@ https://tinyurl.com/Pancreatic-Cancer-Therapeutics .

Report Includes Pancreatic Cancer Pipeline by Companies:

3-V Biosciences Inc, 4P-Pharma SAS, AB Science SA, AbbVie Inc, AbGenomics International Inc, Ability Pharmaceuticals SL, Actuate Therapeutics Inc, Adamed Sp z oo, Aduro BioTech Inc, Advanced Cancer Therapeutics LLC, Advantagene Inc, Agenus Inc, AGV Discovery SAS, AIMM Therapeutics BV, Alissa Pharma, Allinky Biopharma, Almac Discovery Ltd, Altor BioScience Corp, Ambrx Inc, amcure GmbH, American Gene Technologies International Inc, Amgen Inc, Anavex Life Sciences Corp, Andarix Pharmaceuticals Inc, ANP Technologies Inc, AntiCancer Inc, APEIRON Biologics AG, Aphios Corp, APIM Therapeutics AS, Apogenix GmbH, Aposense Ltd, ARMO Biosciences Inc, ArQule Inc, Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, Autotelic Inc, AVEO Pharmaceuticals Inc, Axcentua Pharmaceuticals AB, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene (Beijing) Co Ltd, Bellicum Pharmaceuticals Inc, Berg LLC, BerGenBio ASA, Beta Pharma Inc, Bexion Pharmaceuticals LLC, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, BioLineRx Ltd, Biomar Microbial Technologies, Biomunex Pharmaceuticals, Bioncotech Therapeutics SL, Bionomics Ltd, BioNTech AG, Biotest AG, Biouniversa srl, BLR Bio LLC, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd, Calithera Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Cantargia AB, Cascadian Therapeutics Inc, Cavion LLC, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Celleron Therapeutics Ltd, Cellular Biomedicine Group Inc, Celprogen Inc, Celyad SA, Centrose LLC, Ceronco Biosciences, ChemoCentryx Inc, Chugai Pharmaceutical Co Ltd, Clovis Oncology Inc, COARE Biotechnology Inc, Codiak BioSciences Inc, Concordia International Corp, Confluence Life Sciences Inc, Critical Outcome Technologies Inc, CrystalGenomics Inc, CTI BioPharma Corp, Cyclacel Pharmaceuticals Inc, CytomX Therapeutics Inc, Cytori Therapeutics Inc, CytRx Corp, CyTuVax BV, Daewoong Pharmaceutical Co Ltd, Daiichi Sankyo Company Ltd, DEKK-TEC Inc, Denceptor Therapeutics Ltd, Diffusion Pharmaceuticals Inc, Eisai Co Ltd, Eleison Pharmaceuticals LLC, Eli Lilly and Company, Endor Nanotechnologies SL, Ensemble Therapeutics Corp, Ensol Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Etubics Corp, Exelixis Inc, F. Hoffmann-La Roche Ltd, Faron Pharmaceuticals Oy, FibroGen Inc, Formosa Laboratories Inc, Forty Seven Inc, Fountain Biopharma Inc, Fujifilm Corp, Fusion Antibodies Ltd, Galena Biopharma Inc, GamaMabs Pharma SA, Geistlich Pharma AG, Genelux Corp, Genentech Inc, Genisphere LLC, Genmab A/S, Gilead Sciences Inc, GlaxoSmithKline Plc, Globeimmune Inc, GlycoMimetics Inc, Glycotope GmbH, Golden Biotechnology Corp, GW Pharmaceuticals Plc, Halozyme Therapeutics Inc, Helix BioPharma Corp, Horizon Pharma Plc, Humorigin Biotechnology Corp, iCeutica Inc, Idera Pharmaceuticals Inc, Igenica Biotherapeutics Inc, Ignyta Inc, Immodulon Therapeutics Ltd, Immune Pharmaceuticals Inc, Immune System Key Ltd, Immune Therapeutics Inc, Immunitor Inc, Immunomedics Inc, Immunotope Inc, Immunovo BV, Immupharma Plc, Incyte Corp, Inflection Biosciences Ltd, Innopharmax Inc, Innovation Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Intezyne Technologies Inc, Inventiva, InvivoGen Therapeutics, Io Therapeutics Inc, Ipsen SA, ISU ABXIS Co Ltd, Jasco Pharmaceuticals LLC, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kalyra Pharmaceuticals Inc, Kancera AB, Karcinolys SAS, Karyopharm Therapeutics Inc, Keystone Nano Inc, Komipharm International Co Ltd, Kura Oncology Inc, Kyowa Hakko Kirin Co Ltd, Lead Discovery Center GmbH, Lidds AB, Lion Biotechnologies Inc, Lipopharma Therapeutics SL, Lixte Biotechnology Holdings Inc, Loxo Oncology Inc, Lymphocyte Activation Technologies SA, MabVax Therapeutics Holdings Inc, MacroGenics Inc, Mateon Therapeutics Inc, MaxiVAX SA, Meabco A/S, Mebiopharm Co Ltd, MediaPharma Srl, Medicenna Therapeutics Corp, MedImmune LLC, Medivir AB, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Millennium Pharmaceuticals Inc, Moleculin Biotech Inc, MolMed SpA, Monopar Therapeutics LLC, Morphotek Inc, Mount Tam Biotechnologies Inc, NanoCarrier Co Ltd, NantKwest Inc, Nascent Biotech Inc, Natco Pharma Ltd, NatureWise Biotech & Medicals Corp, NBE-Therapeutics AG, Nerviano Medical Sciences Srl, NewLink Genetics Corp, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, Novogen Ltd, Novus Therapeutics Inc, Noxxon Pharma AG, NuCana BioMed Ltd, OBI Pharma Inc, Omeros Corp, Oncodesign SA, Oncolytics Biotech Inc, Oncomatryx Biopharma SL, OncoMed Pharmaceuticals Inc, OncoTherapy Science Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Onxeo SA, Opsona Therapeutics Ltd, Optimum Therapeutics LLC, Orega Biotech SAS, Oribase Pharma, Oryx GmbH & Co KG, Patrys Ltd, Pfizer Inc, Pharma Two B Ltd, PharmAbcine Inc, PharmaCyte Biotech Inc, Pharmedartis GmbH, Phoenix Biotechnology Inc, Plexxikon Inc, Polaris Pharmaceuticals Inc, Precision Biologics Inc, Prima BioMed Ltd, Propanac Biopharma Inc, Provectus Biopharmaceuticals Inc, Puretech Health plc, Quest PharmaTech Inc, Quimatryx SL, Quintessence Biosciences Inc, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Redx Pharma Plc, Rexahn Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Samumed LLC, Samyang Holdings Corp, Sanofi, Sareum Holdings Plc, SATT North SAS, Selecta Biosciences Inc, Sierra Oncology Inc, SignPath Pharma Inc, Sillajen Biotherapeutics, Soricimed Biopharma Inc, Sorrento Therapeutics Inc, Spring Bank Pharmaceuticals Inc, Stelic Institute & Co Inc, Strongbridge Biopharma plc, Sumitomo Dainippon Pharma Co Ltd, Sun BioPharma Inc, Sun Pharma Advanced Research Company Ltd, Sunshine Biopharma Inc, Swedish Orphan Biovitrum AB, Symic Biomedical Inc, Symphogen A/S, SynCore Biotechnology Co Ltd, Synergys Biotherapeutics Inc, Synovo GmbH, SyntheX Inc, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takara Bio Inc, Takeda Pharmaceutical Company Ltd, Takis Srl, Targovax ASA, Tarveda Therapeutics Inc, tella Inc, Threshold Pharmaceuticals Inc, Tiltan Pharma Ltd, Tocagen Inc, Tolero Pharmaceuticals Inc, Transcriptogen Ltd, Transgene SA, TVAX Biomedical Inc, Tyg Oncology Ltd, Tyme Technologies Inc, Tyrogenex Inc, UbiVac LLC, ValiRx Plc, VasGene Therapeutics Inc, Vault Pharma Inc, Vaxeal Holding SA, Vaximm AG, Vaxon Biotech, VCN Biosciences SL, Vect-Horus SAS, Verastem Inc, VG Life Sciences Inc, Vicus Therapeutics LLC, ViiV Healthcare Ltd, Viralytics Ltd, Virobay Inc, ViroStatics srl, Wilex AG, Zeria Pharmaceutical Co Ltd.

Scope:

-The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology).
Purchase This Report at: https://tinyurl.com/Pancreatic-Cancer-Drugs .

Major Table of Content:

• Introduction
• Pancreatic Cancer - Overview
• Pancreatic Cancer - Therapeutics Development
• Pancreatic Cancer - Therapeutics Assessment
• Pancreatic Cancer - Companies Involved in Therapeutics Development
• Pancreatic Cancer - Drug Profiles
• Pancreatic Cancer - Dormant Projects
• Pancreatic Cancer - Discontinued Products
• Pancreatic Cancer - Product Development Milestones.

Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: sales@reportsnreports.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pancreatic Cancer Pipeline Drugs Review H1 2017 here

News-ID: 612618 • Views:

More Releases from ReportsandReports

The Growing Importance of Smart Wearable Equipment - Global Market: Today's Worl …
The report presents detailed information regarding the prominent players and potential competitors in the Smart Wearable Equipment - Global market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player. This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses
Vegetable Glycerin - Global Market 2023 Driving Factors Forecast Research 2029
This comprehensive report thoroughly assesses various regions, estimating the volume of the global Vegetable Glycerin - Global market within each region during the projected timeframe. The report is meticulously crafted and includes valuable information on the current market status, historical data, and projected outlook. Furthermore, it presents a detailed market analysis, segmenting it based on regions, types, and applications. The report closely monitors key trends that play a crucial role
Underground Concrete - Global Market Booming Worldwide with Latest Trend and Fut …
The report presents detailed information regarding the prominent players and potential competitors in the Underground Concrete - Global market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player. This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses revenue,
Eucalyptol - Global Market was Led by the Solution Category
This comprehensive report thoroughly assesses various regions, estimating the volume of the global Eucalyptol - Global market within each region during the projected timeframe. The report is meticulously crafted and includes valuable information on the current market status, historical data, and projected outlook. Furthermore, it presents a detailed market analysis, segmenting it based on regions, types, and applications. The report closely monitors key trends that play a crucial role in

All 5 Releases


More Releases for Pharma

Antiemetics Market Size 2022 Analysis by Top Key Players| Acacia Pharma Group Pl …
Antiemetics Market research added by the Absolute Markets Insights, offers a comprehensive analysis of growth trends prevailing in the global business domain. This report also provides definitive data concerning market, size, commercialization aspects and revenue forecast of the industry. In addition, the study explicitly highlights the competitive status of key players within the projection timeline while focusing on their portfolio and regional expansion endeavors. Access the PDF sample of the report@
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the
Indometacin Market Top Key Manufacturers Aidarex, Ratiopharm, Merck, Xinhua Phar …
The Global Indometacin Market is a nonsteroidal anti-inflammatory drug commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. The demand for nonsteroidal anti-inflammatory drug has been increasing owing to the emergence of anti-inflammatory biologics that are more targeted. However, such as side effects of anti-inflammatory drugs and patent expiry issues may hamper the market growth in the review period. For More Info, Get Sample Report
Hydroxycarbamide Market Study Report 2019| Taj Pharma, Beijing Jialin Pharma, Qi …
Los Angeles, United State, June 11, 2019, - The global Hydroxycarbamide market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Hydroxycarbamide
TIGLUTIK Market 2019: Top Players are Sanofi, Mylan Pharma, Apotex, Glemark Gene …
TIGLUTIK Market 2019 Report analyses the industry status, size, share, trends, growth opportunity, competition landscape and forecast to 2025. This report also provides data on patterns, improvements, target business sectors, limits and advancements. Furthermore, this research report categorizes the market by companies, region, type and end-use industry. Get Sample Copy of this Report@ https://www.researchreportsworld.com/enquiry/request-sample/13709986 Global TIGLUTIK market 2019 research provides a basic overview of the industry including definitions, classifications, applications